TRIDM-1
Description
- Triple-action formula targeting multiple mechanisms of blood sugar control.
- Glimepiride enhances insulin secretion from pancreatic beta cells.
- Metformin improves insulin sensitivity and reduces hepatic glucose output.
- Voglibose slows carbohydrate digestion to reduce postprandial sugar spikes.
- Helps in maintaining better HbA1c levels in type 2 diabetes.
- Suitable for adults under physician supervision.
- To be taken with meals to minimize gastrointestinal side effects.
Composition
GLIMIPRIDE-1 MG, VOGLOBOSE- 0.2 MG, METFORMINE-500 MG
Benefits
TRI-DM-1/500 provides multifaceted benefits in diabetes management. It effectively lowers both fasting and postprandial blood sugar levels, enhances insulin sensitivity, and minimizes glucose spikes after meals. The inclusion of Voglibose helps reduce the risk of post-meal hyperglycemia, while Glimepiride improves pancreatic insulin release. Metformin complements this by decreasing glucose production and absorption. This combination not only helps improve overall glycemic control but also reduces the risk of diabetes-related complications when used as part of a proper diet and exercise regimen.
Introduction
TRI-DM-1/500 is an advanced triple-drug combination used in the effective management of Type 2 Diabetes Mellitus. It combines Glimepiride, a sulfonylurea that stimulates insulin secretion; Metformin, a biguanide that reduces hepatic glucose production and improves insulin sensitivity; and Voglibose, an alpha-glucosidase inhibitor that slows carbohydrate absorption in the intestine. This synergistic formulation helps in controlling postprandial as well as fasting blood glucose levels, offering comprehensive glycemic control for patients with type 2 diabetes.
